When should beta‑blockers be held before stress testing, and which stress test modalities should be used?

When to Hold Beta-Blockers for Stress Testing

For diagnostic exercise stress testing in patients with suspected coronary artery disease, beta-blockers should be withdrawn prior to testing, though the evidence supports that this can be done safely on the morning of the test rather than requiring days of discontinuation.

Timing of Beta-Blocker Withdrawal

The traditional approach has been to discontinue beta-blockers for several days before diagnostic stress testing 1, 2. However, this recommendation lacks standardization and creates practical problems:

• Abrupt discontinuation risks rebound phenomena including tachycardia, hypertension, and potentially unstable angina, particularly in patients with recent acute coronary syndrome 1, 3
• Most guidelines recommend 24-48 hours of withdrawal but do not specify dose tapering 1
• A practical alternative: Administer half the usual beta-blocker dose on the morning of testing at the regular time 3. This approach balances diagnostic sensitivity while minimizing rebound risk.

Which Stress Tests Require Beta-Blocker Withdrawal

Exercise ECG Testing (Treadmill/Bicycle)

• Hold beta-blockers when performing diagnostic exercise ECG in patients able to exercise with interpretable baseline ECG 4, 5
• Beta-blockers reduce maximum heart rate and rate-pressure product, potentially preventing patients from reaching their ischemic threshold 1
• This decreases diagnostic sensitivity for detecting coronary artery disease

Exercise Stress with Imaging (Echo or Nuclear)

• Hold beta-blockers for exercise stress echocardiography or nuclear imaging when diagnostic accuracy is the primary goal 4, 5
• Beta-blocker therapy significantly decreased accuracy of dipyridamole stress echocardiography (66% vs 84% in patients not on beta-blockers) 6
• However, beta-blockers do not affect the prognostic value of coronary flow velocity reserve (CFVR) 7

Pharmacological Stress Testing

• May continue beta-blockers for vasodilator stress (adenosine, dipyridamole, regadenoson) with imaging 7, 8
• Vasodilator stress works through coronary steal mechanisms rather than increasing myocardial oxygen demand, making it less affected by heart rate control
• One study showed that in the majority of patients, scan results and interpretation remained unchanged with beta-blockers during adenosine stress 8
• Dobutamine stress: Beta-blockers may reduce sensitivity but less so than with exercise 6

Clinical Context Matters

Continue Beta-Blockers When:

1. Prognostic testing in known CAD - The patient is already on optimal medical therapy and you're assessing risk stratification 9, 4, 10
2. Post-ACS risk stratification - Patients should remain on beta-blockers after acute coronary syndrome; perform stress testing while on medications after 12-24 hours of stability 9, 4, 5
3. Preoperative evaluation - In intermediate-risk patients on beta-blockers with tight heart rate control (<65 bpm), cardiac testing can be performed on therapy or even omitted 11
4. Contraindications to withdrawal - Recent MI, unstable angina, severe arrhythmias, or when withdrawal poses greater risk than reduced test sensitivity 1, 3

Withdraw Beta-Blockers When:

1. Initial diagnostic evaluation for suspected CAD in stable patients
2. Evaluating extent/severity of known CAD when revascularization decisions depend on test results
3. Exercise-based testing is planned (treadmill or bicycle ECG)
4. Patient can safely discontinue without rebound risk (no recent ACS, stable chronic angina)

Practical Algorithm

For diagnostic exercise stress testing:

• If patient has been stable on beta-blockers without recent ACS → Give half-dose on morning of test 3
• If recent ACS or unstable → Continue full beta-blocker dose and interpret results accordingly 9, 4

For pharmacological stress with imaging:

• Continue beta-blockers, particularly for vasodilator stress 7, 8
• Ensure adequate heart rate control (<65 bpm) for optimal outcomes 11

For prognostic/risk stratification:

• Continue usual medications including beta-blockers 9, 4, 10
• Focus on functional capacity and symptoms rather than pure diagnostic accuracy

Critical Caveats

• Never abruptly stop beta-blockers in patients with recent acute coronary syndrome without careful monitoring 1, 3
• ST-segment changes and time to ischemia cannot reliably assess CAD extent/severity when testing on beta-blockers 12
• The ST/HR slope remains valid even on beta-blocker therapy and should be measured when interpreting tests performed on therapy 12
• Document medication status at time of testing, including dose and timing of last beta-blocker dose 1